Generex Biotechnology Presents at 2006 Canadian Diabetes Association Conference

Strategic Insights -

Generex Biotechnology, a leading company in drug delivery for metabolic diseases, made a significant presentation at the 2006 Canadian Diabetes Association (CDA) Professional Conference and Annual Meetings in Toronto, Canada. The company highlighted its proprietary oral insulin spray product, Generex Oral-lyn, in a paper titled "3-Month Interim Results (6-Month Study) on Safety and Efficacy of an Oral Insulin (Generex Oral-lyn) Administered at Lunchtime in Juvenile Type-1 Diabetes Mellitus Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin." This presentation was led by Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs, and co-authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra from the Institute of Endocrinology IEMYR in Quito, Ecuador.

In addition to the podium presentation, Generex sponsored several studies that were presented as posters at the CDA conference. These included studies on Generex Metformin Gum: An Alternative Method for Delivery of Biguanides, and peptides in Type 1 Diabetes, among others.

Key Takeaways:

  • Generex Biotechnology presented its proprietary oral insulin spray product, Generex Oral-lyn, at the 2006 Canadian Diabetes Association conference.
  • The presentation highlighted the safety and efficacy of Generex Oral-lyn in a 6-month study on juvenile Type-1 diabetes mellitus subjects.
  • The study was co-authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra from the Institute of Endocrinology IEMYR in Quito, Ecuador.
  • Generex also sponsored several sponsored studies that were presented as posters at the CDA conference.
  • Generex is engaged in the research and development of drug delivery systems and technologies.

Statistics:

  • Generex Oral-lyn is a proprietary oral insulin spray product.
  • The 6-month study involved 12 subjects with juvenile Type-1 diabetes mellitus.
  • The study was conducted in Ecuador.
  • Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity.

Sources:

  • GENEREX BIOTECHNOLOGY CORPORATION Press release, October 19, 2006, Market Wire via COMTEX
  • Generex Biotechnology website, www.generex.com
  • 2006 Canadian Diabetes Association (CDA) Professional Conference and Annual Meetings, Toronto, Canada